Cabozantinib C28H24FN3O5 Pharmaceutical Raw Materials Cabozantinib CAS: 849217

 

Cabozantinib C28H24FN3O5 Pharmaceutical Raw Materials

 

Cabozantinib CAS: 849217-68-1

 

 

 

USP Effectual Apis Cabozantinib 849217-68-1 XL184 for Thyroid Cancer Treatment

Pharmaceutical Raw Powder Cabozantinib (XL184) for Cancer Research CAS: 849217-68-1

Pharmaceutical Intermediates Raw Materials Cabozantinib CAS 849217-68-1

 

 

 

 

Cabozantinib, marketed under the trade name Cabometyx among others, is a small molecule inhibitor of the tyrosine kinases c-Met and VEGFR2, and has been shown to reduce tumor growth, metastasis, and angiogenesis. It was discovered and developed by Exelixis Inc.

Cabozantinib was granted orphan drug status by the U.S. Food and Drug Administration (FDA) in January 2011.Cabozantinib is approved by the U.S. FDA for medullary thyroid cancer.and advanced renal cell carcinoma in people who have received prior anti-angiogenic therapy.It is currently undergoing clinical trials for the treatment of prostate, bladder, ovarian, brain, melanoma, breast, non-small cell lung, pancreatic, and hepatocellular cancers.

Cabozantinib will be distributed in Europe by the French pharmaceutical company Ipsen after a collaboration was reached with Exelixis in March 2016.

Cabozantinib Profile

Product Name: Cabozantinib

Cabozantinib Synonyms: N-(4-(6,7-dimethoxyquinolin-4-yloxy)phenyl)-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide;Cabozantinib;N-[4-[(6,7-Dimethoxy-4-quinolinyl)oxy]phenyl]-N-(4-fluorophenyl)-1,1-cyclopropanedicarboxamide;XL184;Cabozantinib(XL184);XL-184 free base (Cabozantinib);BMS907351;N-(4-((6,7-DiMethoxyquino...

Cabozantinib CAS: 849217-68-1

Cabozantinib MF: C28H24FN3O5

Cabozantinib MW: 502

Cabozantinib EINECS:205-285-7

Cabozantinib Product Categories: Inhibitors

Mol File: 849217-68-1.mol

Cabozantinib Description

Anti-cancer drug Cabozantinib is a kind of a novel type of molecular targeted drug developed by the United States Exelixis biopharmaceutical company. On November 29, 2012, the US Food and Drug Administration (FDA) approved the use of cabozantinib for the treatment of unresectable malignant local advanced or metastatic medullary thyroid carcinoma.

In addition, Sorafenib, Vandernib and Levotinib have been approved by the Food and Drug Administration (FDA) for the treatment of advanced thyroid cancer.

 

Cabozantinib Usage

Uses and fuction:

Cabozantinib interferes with the growth of some cancer cells.

Cabozantinib is used to treat thyroid cancer that has spread to other parts of the body.

Cabozantinib is also used to treat kidney cancer after other cancer medicines have been tried without success.

Cabozantinib may also be used for purposes not listed in this medication guide.

 

Cabozantinib COA:

Tests	Specifications	Results
Characters	White to off-white crystalline powder with a characteristic sulfide-like order	Complies
Identification	IR:similar to Reference Standard	Complies
Appearance of solution	Clear and colorless	Complies
Specific Rotation	-127° -132°	-131°
Loss on Drying	<0.5%	0.06%
Sulphated Ash	<0.2%	0.03%
Heavy metals	<0.002%	Complies
pH	2.0 to 2.6	2.3
Related Compouds	1. 1. Single Impurity <1.0% 2. 2. Sum of Impurity<2.0%	Undetected Undetected
Assay(Anhydrous)	98.0% to 101.5%	100.2%

 

 

Cabozantinib C28H24FN3O5 Pharmaceutical Raw Materials Cabozantinib CAS: 849217 Images